搜尋結果
辉瑞-BioNTech 2019冠状病毒病疫苗[5]（英語：Pfizer–BioNTech COVID-19 vaccine，簡稱：輝瑞BNT疫苗、輝瑞疫苗、BNT疫苗[4]，代號：BNT162b2，商品名：Comirnaty[2]、復必泰，國際非專利藥品名稱：tozinameran[1]），是一種專門對抗严重急性呼吸系统综合征冠状病毒2（SARS-CoV2）的 ...
The Pfizer–BioNTech COVID-19 vaccine, sold under the brand name Comirnaty,[2][32] is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. For its development, BioNTech collaborated with the American company Pfizer to carry out clinical trials, logistics, and manufacturing.[44][45] It is authorized for use in ...
2022年4月1日 · 輝瑞/BioNTech疫苗 你需要了解的幾個問題. 上海市政府最近發佈的政策文件引起廣泛關注，市場揣測進口mRNA新冠疫苗或指日可待，反應迅速。. 上海 ...
4 天前 · Stock analysis for BioNTech SE (BNTX:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Connecting decision ...
BioNTech is a fully integrated, global immunotherapy powerhouse. We have been working on automated and digitized processes and build continuously capabilities for specialized manufacturing, either for individualized vaccines or for large-scale products like our COVID-19 vaccine. We are also continuously evaluating ways to democratize the access ...
BioNTech SE An der Goldgrube 12 55131 Mainz, Germany T: +49 6131 9084-0 F: +49 6131 9084-2121 M: service@biontech.de Company About Research & Innovation Pipeline Manufacturing Careers Covid-19 Quick Links Newsroom Investors Connect ...
The WHO Strategic Advisory Group of Experts on Immunization (SAGE) has issued interim recommendations for the use of the Pfizer BioNTech (BNT162b2) vaccine against COVID-19. This article provides a summary of those interim recommendations; you may access the full guidance document here. Here is what you need to know.
